FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells

Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype

(2016) Feimeng Zheng et al.   Nature Communications

Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma

(2015) Kiyokazu Tamotsu et al.   BMC CANCER

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance

(2015) Gabriela Nestal de Moraes et al.   CELLULAR SIGNALLING

Non-malignant T-cells lacking multiple pan-T markers can be found in lymph nodes

(2015) Wei Wang et al.   LEUKEMIA & LYMPHOMA

Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance

(2015) P Khongkow et al.   ONCOGENE

Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

(2014) Chun Hei Antonio Cheung et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor-Initiating Cells and Overcomes Drug Resistance

(2014) F.-M. Zheng et al.   MOLECULAR CANCER THERAPEUTICS

Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance

(2014) Fung Zhao et al.   PLoS One

FOXM1: A key oncofoetal transcription factor in health and disease

(2014) Laura Bella et al.   SEMINARS IN CANCER BIOLOGY

Lineage-restricted function of the pluripotency factor NANOG in stratified epithelia

(2014) Daniela Piazzolla et al.   Nature Communications

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

(2013) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance

(2013) P Khongkow et al.   ONCOGENE

Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance

(2013) Ana R. Gomes et al.   Chinese Journal of Cancer

A Brief Review on the Human Encyclopedia of DNA Elements (ENCODE) Project

(2013) Hongzhu Qu et al.   GENOMICS PROTEOMICS & BIOINFORMATICS

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

(2012) Y. P. Mosse et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Breast cancer stem cells

(2012) Marco A. Velasco-Velázquez et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

The Forkhead Transcription Factor FOXM1 Controls Cell Cycle-Dependent Gene Expression through an Atypical Chromatin Binding Mechanism

(2012) X. Chen et al.   MOLECULAR AND CELLULAR BIOLOGY

Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202

(2012) Chao Cheng et al.   MOLECULAR PHARMACEUTICS

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment

(2012) L J Monteiro et al.   ONCOGENE

FOXM1: From cancer initiation to progression and treatment

(2011) Chuay-Yeng Koo et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance

(2011) J. Millour et al.   MOLECULAR CANCER THERAPEUTICS

FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer

(2011) C T Karadedou et al.   ONCOGENE

Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer

(2009) U. B. McGovern et al.   MOLECULAR CANCER THERAPEUTICS

Cancer stem cells: mirage or reality?

(2009) Piyush B Gupta et al.   NATURE MEDICINE

Inhibition of Aurora-A suppresses epithelial–mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells

(2008) Xiang-Bo Wan et al.   CARCINOGENESIS

Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression

(2008) J. M-M. Kwok et al.   MOLECULAR CANCER THERAPEUTICS